Nyrada Inc Asset Resilience Ratio
Nyrada Inc asset resilience ratio. Nyrada Inc (NYR) has an Asset Resilience Ratio of 55.29% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Nyrada Inc (NYR) defensive interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Nyrada Inc (2021–2022)
Asset resilience ratio of Nyrada Inc from 2021 to 2022. This chart shows how Nyrada Inc's Asset Resilience Ratio has changed over time. Read NYR total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Nyrada Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Nyrada Inc balance sheet assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$2.93 Million | 55.29% |
| Short-term Investments | AU$0.00 | 0% |
| Total Liquid Assets | AU$2.93 Million | 55.29% |
Asset Resilience Insights
- Very High Liquidity: Nyrada Inc maintains exceptional liquid asset reserves at 55.29% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Nyrada Inc Industry Peers by Asset Resilience Ratio
Compare Nyrada Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Nyrada Inc Asset Resilience Ratio by Year (2021–2022)
Nyrada Inc asset resilience ratio by year from 2021 to 2022. The table below shows the annual Asset Resilience Ratio data for Nyrada Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-06-30 | 90.03% | AU$10.82 Million ≈ $7.65 Million |
AU$12.01 Million ≈ $8.50 Million |
-0.70pp |
| 2021-06-30 | 90.72% | AU$13.75 Million ≈ $9.73 Million |
AU$15.16 Million ≈ $10.72 Million |
-- |
About Nyrada Inc
Nyrada Inc., a pre-clinical stage drug development company, engages in the development of small molecule drugs for cardiovascular and neurological diseases. Its lead candidate is Xolatryp, a small molecule drug which has completed phase 1 clinical trial for neuroprotection and cardioprotection indications and in patients with traumatic brain injury and ischaemic stroke. Nyrada Inc. was incorporat… Read more